1,273 results on '"Hortobagyi G"'
Search Results
2. Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2
3. Perspektiven
4. Methoden und Evidenz des Fortschritts
5. Metastasen (Sekundärtumoren)
6. Weichteilsarkome
7. Maligne Knochen- und Knorpeltumoren
8. Leukämien und Lymphome
9. Krebs des Gehirns und des Nervensystems
10. Krebs der weiblichen Geschlechtsorgane
11. Blasen- und Nierenkrebs
12. Krebs der männlichen Geschlechtsorgane
13. Lungenkrebs (Bronchialkarzinom)
14. Krebs des Verdauungstraktes
15. Krebs im Kopf-Hals-Bereich
16. Brustkrebs (Mammakarzinom)
17. Krebstherapie
18. Symptome von Krebs: Lokal- und Allgemeinsymptome
19. Hautkrebs
20. Klinische Pathologie von Krebserkrankungen
21. Anzeichen von Krebs: lokale und allgemeine Krankheitszeichen
22. Untersuchungsmethoden zur Krebserkennung
23. Was ist eine maligne Erkrankung?
24. Konkrete Maßnahmen zur Krebsprävention
25. Epidemiologie
26. Results of MDR-1 Vector Modification Trial Indicate that Granulocyte/Macrophage Colony-Forming Unit Cells Do not Contribute to Posttransplant Hematopoietic Recovery Following Intensive Systemic Therapy
27. Beziehung zwischen Patienten, Ärzten und Behandlungsteam
28. Radiotherapy Use and Locoregional Recurrence Rates on SWOG 1007, a US Cooperative Group Trial Enrolling Patients with Favorable-Risk Node-Positive Breast Cancer
29. Clinicopathological and surgical factors associated with long-term survival in patients with HER2-positive metastatic breast cancer
30. SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer
31. Comprehensive analysis of factors impacting risks and outcomes of therapy-related myeloid neoplasms following breast cancer treatment
32. Principles and performance of virtual CT and MRI intraluminal endoscopy
33. Development of Clinical Trial of E1A Gene Therapy Targeting HER-2/neu-overexpressing Breast and Ovarian Cancer
34. Aktualisierte Ergebnisse von Tucatinib versus Placebo in Kombination mit Trastuzumab und Capecitabin bei Patienten mit vorbehandeltem, metastasierten HER2-positiven Brustkrebs mit ZNS-Metastasen (HER2CLIMB)
35. Taxol in metastatic breast cancer: the MD Anderson Cancer Center experience
36. Long-term efficacy and late sequelae of Doxorubicin-containing adjuvant therapy for breast cancer: MD Anderson Cancer Center studies
37. Primary chemotherapy for breast cancer: response to preoperative chemotherapy as prognostic factor
38. Metastatic breast cancer: current management options and future directions
39. Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer
40. Ink4a/Arf−/− and HRAS(G12V) transform mouse mammary cells into triple-negative breast cancer containing tumorigenic CD49f− quiescent cells
41. Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy
42. Mammakarzinom
43. Locally Advanced Breast Cancer: A Review Including the M.D. Anderson Experience
44. Treating Young Patients with Breast Cancer: The Evidence Suggests That All Should Be Treated with Adjuvant Therapy
45. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†
46. Outcome of metastatic breast cancer in selected women with or without deleterious BRCA mutations
47. The prognostic impact of age in patients with triple-negative breast cancer
48. Ki67 expression in the primary tumor predicts for clinical benefit and time to progression on first-line endocrine therapy in estrogen receptor-positive metastatic breast cancer
49. Adenovirus 5 E1A enhances histone deacetylase inhibitors-induced apoptosis through Egr-1-mediated Bim upregulation
50. Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.